Search

EHA Friends' Fund

Together, we can change the lives of many and make greater strides in the treatment of patients with blood disorders.

Read more

Novel basis for chemoresistance in AML: DNMT3A R882 mutations promote chemoresistance and residual disease through impaired DNA damage sensing

Although most acute myeloid leukemia (AML) patients initially respond to chemotherapy, the majority subsequently relapses and succumbs to refractory disease. Residual leukemic cells that survived chemotherapy may persist over time and later cause the disease to come back.

Read more

Regulatory affairs & scientific relations

EHA’s regulatory work: European Medicines AgencyMost of EHA’s regulatory work entails collaboration with the European Medicines Agency (EMA).

Read more

SWG Educational Activities

During the annual meeting of EHA, a scientific session was organized: “Mesenchymal stromal cells: guardians of tissue homeostasis”.

Read more

EHA-SWG Scientific Meeting on Integrated Cell Tracking in Oncohematology: Diagnosis, Targeted Therapy and Residual Disease

Dates: November 10-12, 2022
Location: Bordeaux, France
Format: Hybrid
Chair: MC Béné

Registration has closed

This was the third time EHA is collaborating with the EHA Specialized Working Group on Diagnosis in hematological diseases, to bring you the latest in laboratory hematology.…

Read more

Highlights of Past EHA (HOPE ) Asia 2021 - report

In the first weekend of September (September 3-4), EHA opened the virtual platform for HOPE Asia 2021.

Read more

Sponsor opportunities

The European Hematology Association (EHA) invites you to support the EHA Research Conference 2025, titled "Transcriptional control and chromatin alterations in normal and abnormal hematopoiesis" 

This meeting enables the industry to network with delegates, demonstrate their products and present their latest material…

Read more